Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
| ▸ | CD22 | P20273 | 15/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAG | P20916 | 2/20 | 0.38 |
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18733276 | 0.88 | CD22 (0.43) | CD22MAGSIGLEC7 | |
| SCHEMBL31668635 | 0.88 | CD22 (0.43) | CD22MAGSIGLEC7 | |
| SCHEMBL18732828 | 0.88 | CD22 (0.43) | CD22MAGSIGLEC7 | |
| SCHEMBL16190424 | 0.85 | SELL (0.44) | SELLSELPCD22MAG | |
| SCHEMBL12694360 | 0.85 | CD22 (0.42) | CD22MAGSIGLEC7 | |
| SCHEMBL18733280 | 0.82 | L3MBTL1 (0.46) | SELLSELPCD22L3MBTL1MAG | |
| SCHEMBL12898682 | 0.81 | MAG (0.49) | SELLSELPCD22MAGSIGLEC7 | |
| SCHEMBL29392242 | 0.81 | L3MBTL1 (0.42) | SELLSELPCD22L3MBTL1MAG | |
| SCHEMBL18733411 | 0.81 | MAG (0.43) | CD22MAG | |
| SCHEMBL27525510 | 0.80 | L3MBTL1 (0.45) | SELLSELPCD22L3MBTL1MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441024-B2 | Glycosylated polypeptide and drug composition containing said polypeptide | GLYTECH, INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20140315800-A1 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide | GLYTECH, INC. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315800-A1 | Glycosylated Polypeptide and Drug Composition Containing Said Polypeptide | GIPR, SSTR3, SSTR4 | SELL 188/4885SELP 220/4885CD22 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.